---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-235212"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2025-10-09T23:59:59+00:00"
generated_at: "2026-05-17T04:13:37.844107+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Taysha reports 100% milestone response in Phase 1/2 REVEAL Part A for TSHA-102; 165 additional functional gains

## Summary
- All 10 patients (Part A) achieved ≥1 natural-history-defined developmental milestone post-TSHA-102, 0% to <6.7% likelihood without treatment.
- 22 developmental milestones gained across domains of communication, fine motor, gross motor.
- Supplemental analysis: 165 additional skills/improvements across all 10 patients from structured scales (MSEL-A, R-MBA, ORCA).
- Data presented at 54th CNS Annual Meeting; reinforces broad, multi-domain impact on activities of daily living.
- Study evaluates high dose (1x10^15 vg) and low dose (5.7x10^14 vg) in females aged 6-21 years with Rett syndrome.

## SEC filing metadata
- accession: 0001193125-25-235212
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2025-10-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312525235212/0001193125-25-235212-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312525235212/d949053d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-235212
- JSON: https://secwatch.observer/filing/0001193125-25-235212.json
- Plain text: https://secwatch.observer/filing/0001193125-25-235212.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.